Top Markets
Coin of the day
Medtronic plc Medtronic plc

Medtronic plc

2M6
Rank in Stocks #164
Medtronic plc develops, manufactures, and sells device-based medical therapies... Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Share Price
$88.89
Market Cap
$114.13B
Change (1 day)
-0.93%
Change (1 year)
-2.08%
Country
IE
Trade Medtronic plc (2M6)

Category

P/E ratio for Medtronic plc (2M6)
P/E ratio as of March 2026 TTM: 24.21
According to Medtronic plc latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 24.21. At the end of 2024 the company had a P/E ratio of 28.98.
P/E ratio history for Medtronic plc from 2000 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) 24.21 3.61%
2025 23.37 -19.35%
2024 28.98 -9.95%
2023 32.18 15.76%
2022 27.80 -43.06%
2021 48.83 75.64%
2020 27.80 9.46%
2019 25.40 -28.52%
2018 35.53 24.91%
2017 28.44 -9.80%
2016 31.53 -0.78%
2015 31.78 65.27%
2014 19.23 40.13%
2013 13.72 23.30%
2012 11.13 -23.39%
2011 14.53 -6.85%
2010 15.60 -5.77%
2009 16.55 -32.91%
2008 24.67 13.60%
2007 21.72 -8.07%
2006 23.62 -33.21%
2005 35.37 13.16%
2004 31.26 -13.97%
2003 36.33 -33.97%
2002 55.03 7.28%
2001 51.29 -9.73%
2000 56.83 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
28.93 19.47%
US
39.68 63.89%
US
24.21 0.00%
IE
35.47 46.47%
US
20.43 -15.63%
DE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.